Cypress Pays $2.8M To Settle FCA Suit Over Unapproved Drugs
Generic-drug maker Cypress Pharmaceutical Inc. reached a $2.8 million deal with the U.S. Department of Justice to settle a False Claims Act whistleblower case alleging the company and its subsidiary sold...To view the full article, register now.
Already a subscriber? Click here to view full article